My Health Record rule forces telehealth interoperability

DoHDA's plan to require online prescribers to push medicines data into My Health Record by 2027 has turned interoperability into an urgent procurement and product roadmap item for telehealth platforms, prescribing systems and practice management vendors.

Across the week policy moves and commercial shifts combined to raise the cost of standing still. DoHDA’s medicines‑data requirement, the July 1 assignment of benefit signature and retention rules, and tighter TGA guidance around compounding all increase auditability and recordkeeping demands. Winners are vendors that already embed My Health Record connectivity, consent capture and forensic audit trails. Clinics and small pharmacies that still rely on manual processes face either rapid software upgrades or higher compliance risk. For health tech buyers this forces a trade off: prioritise systems with native national‑record links and consent workflows now, or accept short term savings and higher operational risk during inspections and claims submissions.

Clinical access and care pathways are shifting at the same time. AstraZeneca’s withdrawal of the Zoladex 3.6 mg implant and its sponsor‑run Access Program creates an immediate procurement and workflow problem for oncology services that dispensed nearly 30,000 doses this year. At the same time the National Lung Cancer Screening rollout has recruited over 90,000 people since 2025, and the Lancet series that reframes chronic kidney disease points toward routine urine testing and combined cystatin C measures for better eGFR. Those changes put primary care and community providers at the centre of case finding and treatment continuity. Partnerships such as Alcidion’s Miya Precision work with Gold Coast Health show how RPM and clinician‑led feature roadmaps can get clinics the integrations and decision support they need faster. The consequence for executives is clear: procurement choices will not be judged only on price but on how well a vendor connects clinical workflows across screening, medicines management and sponsor programs.

Cautionary note. Two counterweights threaten a clean rollout. Public trust in automated tools is weak — OAIC data shows a sharp rise in privacy concern and only about four per cent of people trust AI — and the proposed 10‑year cap on RDTI risks chilling longer development projects. If regulators demand uploads and logging without matching implementation funding and clear standards, vendors will rush bolt‑on connectors and health services will be left managing brittle integrations and privacy complaints. That failure mode advantages large incumbents able to absorb compliance costs and disadvantages small suppliers, regional practices and aged care providers. Executives must therefore demand implementation timelines, funding support and certified interface standards from procurement partners before signing up to the new interoperability norms.